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Abstract
Measles transmission has been well documented in healthcare facilities. Healthcare personnel who
are unvaccinated and who lack other evidence of measles immunity put themselves and their
patients at risk for measles. We conducted a systematic literature review of measles vaccination
policies and their implementation in healthcare personnel, measles seroprevalence among
healthcare personnel, measles transmission and disease burden in healthcare settings, and impact/
costs incurred by healthcare facilities for healthcare-associated measles transmission. Five
database searches yielded 135 relevant articles; 47 additional articles were found through cross-
referencing. The risk of acquiring measles is estimated to be 2 to 19 times higher for susceptible
healthcare personnel than for the general population. Fifty-three articles published worldwide
during 1989–2013 reported measles transmission from patients to healthcare personnel; many of
the healthcare personnel were unvaccinated or had unknown vaccination status. Eighteen articles
published worldwide during 1982–2013 described examples of transmission from healthcare
personnel to patients or to other healthcare personnel. Half of European countries have no measles
vaccine policies for healthcare personnel. There is no global policy recommendation for the
vaccination of healthcare personnel against measles. Even in countries such as the United States or
Finland that have national policies, the recommendations are not uniformly implemented in
healthcare facilities. Measles serosusceptibility in healthcare personnel varied widely across
studies (median 6.5%, range 0%-46%) but was consistently higher among younger healthcare
personnel. Deficiencies in documentation of two doses of measles vaccination or other evidence of
immunity among healthcare personnel presents challenges in responding to measles exposures in
healthcare settings. Evaluating and containing exposures and outbreaks in healthcare settings can
be disruptive and costly. Establishing policies for measles vaccination for healthcare personnel is
an important strategy towards achieving measles elimination and should be a high priority for
global policy setting groups, governments, and hospitals.
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Introduction
Measles, a highly infectious viral disease characterized by a febrile respiratory prodrome
and a generalized maculopapular rash, can lead to severe complications and death [1]. In
1980, before widespread measles vaccine use globally, an estimated 2.6 million measles-
associated deaths occurred worldwide [2]. With implementation of routine measles
immunization policies globally, there have been dramatic reductions in measles morbidity
and mortality [1].
The World Health Organization (WHO) has established global measles goals focusing on
reduction of measles mortality (≥95% compared with 2000 levels) and achievement of
regional measles elimination1 [3]. Achieving these goals will pave the way for a variety of
achievements including reducing childhood mortality by two-thirds between 1990 and 2015
(i.e., the Millennium Development Goal #4) [4], establishing a target date for global measles
eradication [4, 5], and ultimately, accomplishing the vision of “achieving and maintaining a
world without measles” [3]. Measles was eliminated from WHO’s Region of the Americas
in 2003 [6, 7] and the Pan American Health Organization is currently certifying measles and
rubella elimination for every country in the Region [8]. Elimination goals for 2015 have
been established for four other WHO regions in the world [9, 10]. Nonetheless, measles
remains endemic in Europe, Asia, Africa, and the Middle East [11] leading to measles
importations and outbreaks in many countries that have achieved elimination [12–16].
The majority of measles cases occur in the community but due to the severity of measles, ill
persons are likely to seek medical care in primary healthcare facilities, emergency
departments, or hospitals resulting in nosocomial/healthcare-associated transmission. The
high potential for transmission of measles poses considerable challenges in healthcare
facilities, particularly because the illness may not be recognized immediately resulting in a
failure to implement appropriate isolation precautions [17–19]. Patients can be highly
contagious in the prodromal phase prior to rash onset [1]. Healthcare personnel, including
students in healthcare fields who have clinical rotations and volunteers in medical facilities,
should be protected against measles either through vaccination or other acceptable evidence
of measles immunity [20, 21]. However, measles outbreaks occurring over the last decade
have continued to document the problem of healthcare personnel acquiring and transmitting
measles, suggesting deficiencies in establishing or implementing measles vaccine policies
for this occupational group [18, 22–24].
We conducted a systematic review of literature regarding measles vaccine policies for
healthcare personnel, measles seroprevalance, disease burden and transmission in healthcare
personnel and impact/costs incurred by healthcare facilities for healthcare-associated
measles transmission. This information is intended to help policy makers make, implement,
and evaluate policies to prevent measles transmission to and from healthcare personnel.
1absence of circulation of measles virus >12 months.
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Methods
We reviewed the following databases from the dates indicated through January 2013:
PubMed (June 1973), CINAHL (June 1990), Web of Science (1982), Embase (1988), and
Ovid Medline/Ovid OLDMedline (1946). We used the following search terms: (“measles”
or “MMR vaccine” or “measles transmission” or “measles vaccine policy”) and (“healthcare
workers” or “health-care workers” or “health care workers” or “healthcare personnel” or
“health-care personnel” or “health care personnel”). We included articles written in English.
We also cross-referenced articles referenced in the above searches that were not captured in
the online database searches. Additionally, we conducted a Google search of governmental
health agencies (e.g., Public Health Agency of Canada, Public Health England), as well as
international health agencies (e.g., WHO), to search for measles vaccine policies and
measles evidence of immunity requirements. For calculating summary statistics (mean,
median, interquartile range) for percent of healthcare personnel who were measles
seronegative by region, we excluded studies that reported on a non-representative sample
(i.e., those reporting only on persons without evidence of measles immunity).
Results
Literature search findings
The database searches yielded 135 relevant articles out of 931 potential articles retrieved and
an additional 47 articles were found through cross-referencing for a total of 182 relevant
articles. Of these, we included 125 articles in the results section of the review. The
remaining 57 articles had outdated findings on vaccine coverage, were previous versions of
articles that had subsequently been updated, did not have results broken down by antigen,
had serosurvey results based on vaccination rather than titers, were review articles that
included references we had already cited, or were commentaries that provided no new
information.
Vaccination policies and their implementation in healthcare personnel
Globally, the WHO recommends measles vaccination for susceptible adults but there is no
specific WHO policy recommending measles vaccination or evidence of measles immunity
for healthcare personnel [25]. The United States was the first country to establish a measles
vaccine policy for healthcare personnel in 1987 [26] though measles vaccine had been
recommended for eligible persons of all ages who were considered “susceptible” since 1977
[27]. A number of other countries have policies for measles vaccination of healthcare
personnel including Canada, Australia, countries of the Caribbean and some countries in
Europe [28–31]. As of 2011, Maltezou et al. reviewed vaccination policies for healthcare
personnel in acute healthcare facilities in Europe through surveying infection control or
occupational health providers in all 27 European Union member states, as well as Norway,
Russia and Switzerland. Of the 30 countries, 15 had no measles vaccination
recommendations for healthcare personnel, 12 countries (i.e., Belgium, Cyprus, Germany,
Ireland, Italy, Lithuania, Luxemburg, Malta, Russia, Spain, Switzerland and the United
Kingdom [UK]) recommend measles vaccination for all healthcare personnel, France
recommends vaccination for healthcare personnel in direct patient care, Austria recommends
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vaccination for pediatricians only, and Finland has a policy for mandatory measles
vaccination of healthcare personnel [32]. In France, measles is one of 4 vaccines that is
recommended for healthcare personnel (as well as influenza, pertussis, and varicella), in
contrast to 5 other vaccines (diphtheria, tetanus, poliomyelitis, hepatitis B virus, and
tuberculosis) which are mandated for healthcare personnel [33]. A study in Japan in 2008
reported that vaccination of medical students in Japan was not mandatory [34].
To support implementation of vaccine policy, the United States defined criteria for
“evidence of measles immunity” in 1978 [35]. Since a number of children and the majority
of adults in the population had experienced measles disease when the measles vaccine
program was implemented, these definitions were established to guide healthcare personnel
in decision making regarding who needed measles vaccine. Persons were considered
immune to measles if they had documentation of: 1) adequate (age-appropriate)
immunization with a single dose of live measles vaccine on or after the first birthday, 2)
physician-diagnosed measles, 3) laboratory evidence of measles immunity (measles
Immunoglobulin G [IgG] antibodies, or 4) birth before 1957, since most persons born before
1957 were considered to have been naturally infected and, therefore, were not considered to
be susceptible. These definitions were further refined in 1998 [36] and for healthcare
personnel in 2011 to require written documentation of 2 doses of live measles or MMR
vaccine administered at least 28 days apart (both on or after the first birthday), laboratory
evidence of immunity, laboratory confirmation of disease, or birth before 1957 except
during outbreaks [37]. Physician diagnosis of prior measles disease is no longer considered
acceptable evidence of immunity in the United States [38]. Measles evidence of immunity
requirements for healthcare personnel in Canada and the UK are similar to the United States,
except there are no exclusions based on birth year [28, 39] and Australia has accepted birth
year before 1966, 2 doses of MMR vaccine or serologic evidence as evidence of immunity
[29]. France requires 2 doses of vaccine for healthcare personnel born after 1980 and one
dose for those born before 1980, unless they have a documented history of disease or
vaccination [31].
The presence of a national measles vaccine policy for healthcare personnel does not
guarantee implementation. In the United States in 2004–2005, although over half of states
(n=32) had laws for vaccination (for any vaccine) of healthcare personnel in traditional
healthcare settings (e.g., hospitals, ambulatory care), few laws regulating vaccine
administration for healthcare personnel included penalties for non-compliance [40].
Approximately 80% of states do not have laws requiring the vaccination of healthcare
personnel with measles-containing vaccine [41]. Even among states that do have policies, in
many cases, there is room for interpretation on whether those policies are mandatory or
optional [41]. Studies of healthcare professional schools in the United States between 2001
and 2011 found rates of compliance regarding a measles vaccine requirement ranging from
90% to 98% [42, 43]; however, Miller et al. found that 67 (12.3%) of 547 schools that
responded to their survey accepted at least one form of immunity evidence that is not
recommended (i.e., disease history which was not verified by a physician, acceptable
evidence in the United States at the time, although no longer acceptable) and 156 (28.4%)
allowed any non-medical exemption to vaccination, including exemptions based on personal
beliefs against the vaccination [44].
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In a 2008 study in England of 104 (64.2%) hospital trusts, all respondents offered MMR
vaccine to healthcare personnel. However, only 48 (46.2%) hospital trusts had information
recorded in a central database on MMR vaccinations [45]. In a survey in France in 2011,
17% of occupational physicians from 30 healthcare institutions reported that measles
vaccinations were never suggested to healthcare personnel at their annual occupational
health visit [46].
Global measles control and measles seroprevalence among healthcare personnel
Before use of measles vaccines, almost all adults had natural infection in childhood and
were immune to measles [1]. Regions of the world where measles is still endemic may
currently have a low proportion of healthcare personnel with seronegative measles titers due
to natural infection (e.g., in a study in Uganda, all 311 [100%] sera tested of randomly
selected healthcare personnel in a nationwide study were positive for measles IgG) [47].
However, this is likely to change, especially among young healthcare personnel, as WHO
regions implement regional measles elimination goals.
Studies from most regions of the world have described proportions of healthcare personnel
without measles IgG antibodies ranging from 0–46% (median 6.5%) [17, 18, 22, 47–98]
(Table 1). The proportion of healthcare personnel without measles IgG antibodies was
lowest in Africa (median 1.8%, interquartile range 0.9%– 2.6%) and highest in Asia and the
Western Pacific (median 10.3%, interquartile range 7.2%- 12.2%) and the Middle East
(median 9.2%, interquartile range 4.6%- 13.4%). (Table 2). Thirteen studies among students
in healthcare professions found a median measles seronegativity rate of 14.0% (range 1.2% -
46.0%) [49, 50, 57, 58, 60, 63, 64, 73, 81–83, 86, 98] (Table 1).
In the measles pre-elimination era in the United States (i.e., before 2000), studies during
1981 and 1999 reported a range of 2.1%- 14% of healthcare personnel who lacked measles
antibodies [17, 84–95] (Table 1). The percentage of seronegative personnel was dependent
on age, with older healthcare personnel more likely to have had natural infection and,
therefore, higher measles seroprevalence [17, 84, 87–89, 92, 93, 95]. Two studies from the
post-elimination era conducted in 2008 and 2009 reported that among the subset of
healthcare personnel without documentation of measles immunity who had serologic testing
done, 9% and 11.6% lacked measles antibodies [18, 97]. However, if we assume persons
with documented receipt of two doses of vaccine and persons born prior to 1957 are
immune, then the overall susceptibility of all healthcare personnel in the study institutions
would have been 1.9% and 4.8% [18, 97]. In a study published in 2010, Weber et al.
reported that 1.3% of healthcare personnel born before 1957 lacked antibodies to measles
[96].
Studies from Europe on measles seroprevalence of healthcare personnel published between
1994 and 2013 reported that a median of 6.0% (interquartile range 3.3%-14%) of healthcare
personnel were seronegative to measles, including those who thought they had a history of
measles disease and/or history of measles vaccination [22, 48–65]. These articles also found
differences in seroprevalence based on age, with older personnel less likely to be
seronegative [49, 51–55]. For instance, in France, although overall 4% of healthcare
personnel in one healthcare facility were measles seronegative, this proportion was almost 4-
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fold higher in younger personnel (11% for those aged ≤ 30 years versus 3% for those >30
years) [53].
Only one study from Central or South America on seroprevalence of healthcare personnel
was retrieved; the authors reported that during 1998, 1.2% of medical residents in a pediatric
hospital in Mexico were seronegative to measles [98]. In Asia and the Western Pacific,
studies published between 1994–2012 found 1.7%- 18.9% (median 10.3%) of healthcare
personnel had negative measles titers [66–73] with younger age groups at higher risk for
being measles seronegative [67, 68, 70–72]. Studies from the Middle East published
between 2005–2012 found a median proportion of healthcare personnel who were
seronegative of 9.2%, with seronegativity ranging from 1.4% in a study of healthcare staff in
Turkey to 46% in medical students in United Arab Emirates [74–82]. In South Africa, a
study published in 1990 found 3.5% of 433 medical, nursing, dentistry, and speech/hearing
students tested seronegative for measles [83].
Measles in healthcare settings
The problem of nosocomial measles transmission, including the associated high mortality
and morbidity, has been documented in two reviews [20, 21]. Deaths from measles acquired
in hospital settings highlight that patients exposed to measles in hospitals may be at
increased risk for severe outcomes from measles due to age, underlying medical conditions
and/or medications that result in an immunocompromised state [99]. Transmission of
measles in hospitals and emergency rooms was described during the 1989–1991 U.S.
measles resurgence [100] and these settings continue to be documented as sites of measles
transmission in recent years in countries around the world [18, 22–24]. In rural communities
in developing countries, nosocomial transmission is less well documented as a problem
possibly because access to health facilities or their use by community members for diseases
such as measles is more limited [21].
Healthcare personnel are at higher risk of acquiring measles than other adults with three
studies estimating the risk to be 2, 13 and 19 times higher for susceptible healthcare
personnel than for the general population [100–102]. Due to their higher susceptibility,
young healthcare personnel (<30 years of age) are at higher risk of becoming infected with
measles in work settings than older healthcare personnel [52, 103].
Measles transmission from patients to healthcare personnel has been well documented from
studies in the U.S. prior to, during and after the 1989–1991 measles resurgence [17, 18, 84,
85, 89, 90, 97, 99–102, 104–112]. During 1980–1984, surveillance data from 30 states in the
U.S. showed that 57 (23.7%) of 241 healthcare–associated measles infections occurred in
healthcare personnel [104] and from 1985–1989, 300 healthcare personnel were reported to
have acquired measles from patients [101]. During the 1989–1991 U.S. measles resurgence,
there were many reports of healthcare personnel who developed measles due to
occupational-related exposures [89, 90, 99, 108–110, 112], including personnel who were
born before 1957 [112] and some who had preexisting positive measles antibody titers (i.e.,
not all measles serologic assays are 100% specific for measles immunity and false positives
may occur, albeit rarely and some studies were conducted before the establishment of what
was considered to be the protective level of measles antibody titers) [90]. Post-resurgence
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and in the elimination era in the United States, measles cases have continued to be reported
occasionally among healthcare personnel, including a one-dose vaccinated healthcare
provider who required 6 days of mechanical ventilation in a hospital [111] and a healthcare
provider with unknown vaccination status who acquired measles from a patient and
subsequently transmitted it to another patient [18].
In Europe, Asia and the Western Pacific, articles published mainly over the last decade
including as recently as 2013 have documented measles cases in healthcare personnel
because of exposures from patients; many of the healthcare personnel were unvaccinated,
had unknown vaccination status or thought they were up-to-date with their vaccinations but
actually were not [14, 22–24, 52, 53, 65, 103, 113–137].
Transmission of measles from healthcare personnel to patients or to other healthcare
personnel has also been documented from the United States, Australia, Korea, France, Italy,
Spain, and Bulgaria [18, 22, 24, 52, 84, 100, 101, 103–107, 110, 127, 130, 131, 138, 139]. In
the United States during 1985–1989, of 295 measles cases among patients and visitors to
healthcare facilities who had a known source of infection, 31 (10.5%) acquired measles from
healthcare personnel; additionally, 31 (9.4%) healthcare personnel acquired measles from
another healthcare personnel [101]. In the post-elimination era, during a measles outbreak
that was focused in healthcare facilities, a healthcare provider transmitted measles to a
patient who developed complications requiring admission to the intensive care unit [18].
Impact/ costs of responding to measles in healthcare facilities
Costs of measles outbreaks in healthcare facilities have been assessed in the United States
only. In the pre-elimination era, two studies documented absence of documentation of
vaccination or immunity status that resulted in the need for vaccination of healthcare
personnel, loss of employee work days or both [17, 99]. In the post-elimination era in the
United States, 3 studies reported costs of responding to a measles outbreak in healthcare
facilities. In 2005 in Indiana, one hospital spent more than $113,000 responding to a measles
outbreak with 3 hospitalizations including a one-dose vaccinated healthcare provider
(phlebotomist) who required six days of ventilator support in an intensive care unit for
pneumonia complicated by acute respiratory distress syndrome [111]. In 2008 in Arizona,
two hospitals spent a combined $799,136 responding to and containing seven measles cases
in their facilities. Additional costs were incurred due to vaccination of healthcare personnel.
The Arizona outbreak response required rapid review of measles documentation of 14,844
healthcare personnel at seven hospitals and emergency vaccination of approximately 4,500
(30%) healthcare personnel who lacked documentation of measles immunity [18]. In 2008 in
Chicago, one measles case-patient who spent 63 minutes in the emergency department
without proper isolation led to 201 potential exposures and resulted in over 600 hours spent
by staff in 12 departments on response activities for a financial impact of $18,900 [140].
Discussion
Due to the infectiousness of measles and the status of measles control globally, the risk of
measles transmission in healthcare settings remains a serious concern. Measles has the
highest reproduction rate (Ro) of any of the vaccine-preventable diseases and transmission
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frequently takes place before the onset of rash, impeding the potential effectiveness of
isolation measures in preventing transmission [141]. Nosocomial measles puts healthcare
personnel and patients at risk of severe morbidity and mortality. This health burden and the
public health impact of measles in healthcare facilities underscores the importance of
ensuring protection of healthcare personnel through vaccination. Nevertheless, many
countries lack policies to protect healthcare personnel against measles. Maltezou et al,
following a systematic review of national vaccination policies for healthcare personnel in
Europe, noted that policies related to two vaccines, hepatitis B and influenza, were
implemented in almost every (29 of 30) country in Europe, whereas only half the countries
had any recommendations for measles vaccination [32]. The authors surmised that long-
standing recommendations issued by the WHO for hepatitis B vaccination of healthcare
personnel and the 2000 European Union directive and 2005 WHO recommendations to
increase seasonal influenza vaccine were instrumental in promoting national vaccine policy
setting for these 2 vaccines. Despite the risk of measles exposures and the effectiveness of
vaccination in preventing measles transmission, there is currently no global WHO policy for
the vaccination of healthcare personnel against measles [25].
The potential for healthcare personnel to acquire and/or transmit measles depends on the
stage of the country’s measles vaccine program. Globally, young healthcare personnel are
much more likely to be susceptible; however, in countries where measles has been
eliminated and vaccine coverage is high, the highest measles susceptibility may be in older
cohorts [18, 142]. With improved measles control, changes in measles epidemiology and
implementation of case-based measles surveillance in countries throughout the world, data
on sources of exposure and occurrence of measles cases in healthcare personnel and patients
are available to provide key scientific evidence for vaccine policy decision making. In
Australia, a measles outbreak in the late 1990s that was sparked by a young adult returning
from overseas highlighted the changing measles epidemiology in Australia [134]. The
median age of case-patients was 22 years and the fact that 5 cases occurred in healthcare
personnel spotlighted that there was no systematic, uniform approach to preventing
nosocomial transmission of vaccine-preventable diseases in Australia. This prompted the
state of Victoria to publish immunization guidelines for healthcare personnel in 1998 and
Australia to publish national guidelines [29].
There are also unique challenges in elimination or near-elimination environments. Since
measles is not a common disease in many countries, it may not be considered as a potential
diagnosis when an infected person presents in a healthcare setting resulting in a delay in
instituting the appropriate airborne precautions and increasing the risk of transmission [18].
Additionally, the severity and contagiousness of measles before rash onset results in measles
exposures in healthcare settings before it is recognized that the patient has measles [18]. The
only strategy to protect healthcare personnel from these exposures is to ensure that all
healthcare personnel are protected from measles on an ongoing basis.
An essential component of implementation and evaluation of MMR vaccine policies for
healthcare personnel is defining and documenting criteria for evidence of measles immunity.
Not all healthcare personnel require measles vaccine; many may have naturally acquired
immunity, especially older healthcare personnel and those from countries where measles
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remains endemic [17, 47, 84, 87–89, 92, 93, 95]. Evidence of measles immunity is also
essential for interpreting data on measles vaccine coverage among healthcare personnel.
With rare exception [143, 144], most of the articles we reviewed which reported on
vaccination coverage did not describe whether healthcare personnel had other evidence of
measles immunity, making it impossible to assess true vaccination coverage and the
potential numbers of susceptible healthcare personnel. These issues also complicated
interpreting studies on measles susceptibility in healthcare personnel; while some studies
were comprehensive and representative in testing all or almost all healthcare personnel
irrespective of evidence of measles immunity, many studies did not provide details
regarding the subset of healthcare personnel tested. Additionally, test methods for measles
IgG vary in sensitivity and specificity complicating comparisons across studies.
Although it is recognized that criteria for evidence of immunity do not provide 100%
guarantee that the person is “immune” (e.g. 2 doses of measles vaccine are not 100%
effective, laboratory tests may have false positive and negative results, and IgGs measured
using commercially available tests provide less assurance regarding “protection” than the
level of antibodies measured by the plaque reduction neutralization assay) [90, 97, 145], for
practical program implementation, these criteria have been very useful. Documenting
evidence of measles immunity, particularly in a computerized system, facilitates retrieval of
vaccination records to enable rapid identification of potentially susceptible healthcare
personnel following measles exposures in healthcare facilities which reduce the disruptions
and the costs associated with measles in such facilities [18, 20, 37].
Monitoring vaccine coverage on a country or hospital-specific level is an important
component of a vaccine program for ensuring measles immunity in healthcare personnel.
Only one published article from France documented national tracking of measles vaccine
coverage among healthcare personnel from occupational health records, though interpreting
these data was limited because the authors did not report whether unvaccinated staff had
other evidence of measles immunity [146]. There was wide variability in reported vaccine
coverage in specific healthcare facilities or healthcare training institutions that could be due
to several factors: age group (e.g., healthcare personnel aged <30 years had significantly
higher coverage rates than older personnel though this may also reflect not taking into
account other evidence of measles immunity in the older age group), lack of implementation
or enforcement of national vaccination recommendations at specific institutions [18, 140], or
status of measles elimination at the country-level (e.g., only 47% of healthcare personnel in
Uganda reported having received measles vaccine, but 100% had positive measles IgG tests)
[47].
An association between vaccine policy recommendations and vaccine coverage levels
achieved in healthcare personnel has been demonstrated for influenza vaccine. Mandatory
vaccination policies, if enforced with consequences for non-compliance, are associated with
the highest vaccine coverage rates for influenza vaccines, though vaccine coverage levels
close to 90% have been reached through implementing strategies to encourage vaccination
at the work site [147, 148]. However, healthcare personnel or related organizations may
object to mandatory policies on the grounds that such policies are a breach of individual
rights. Therefore, the individual and public health benefit of the intervention must be clear
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and a mandate should require an active opt-out or allow for exemptions for medical,
religious or other beliefs and there should be some penalty for refusing to abide by it [149].
In a recent study, only 582 (47.9%) healthcare personnel surveyed in Germany supported
mandatory vaccination of healthcare personnel against MMR and varicella [150].
Consideration should also be given to whether a mandate is the only way to obtain
individual medical and/or public health benefits [149]. On the other hand, healthcare
facilities need to consider the medical and legal consequences should one of their employees
who refused immunization become ill and transmit measles to patients, such as those with
immunocompromising conditions who cannot be vaccinated and are only protected from
measles through herd immunity and lack of exposure. Measles vaccine programs pose fewer
challenges for implementation than annual influenza vaccination. Implementation strategies
may include checking evidence of immunity for all incoming healthcare personnel and
vaccination as needed. In addition, efforts should be made to check the status of immunity of
currently employed healthcare personnel and provide vaccination to those in need.
Measles transmission in healthcare settings remains a serious public health concern that may
result in severe and fatal consequences in high risk patients. Measles cases and outbreaks in
these settings result in significant disruption and response costs. Occupational health
departments play a critical role in ensuring that healthcare personnel have evidence of
measles immunity with appropriate documentation. Electronic records are the preferable
mechanism for maintaining this information and are critical to providing a rapid, efficient
public health response to measles exposures. Establishing policies for measles vaccination
for healthcare personnel is an important strategy towards achievement of measles
elimination and should be a high priority for global policy setting groups, governments, and
hospitals.
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e w
er
e s
ta
ff 
ve
rs
us
 p
at
ie
nt
s/f
am
ily
. T
he
 p
er
ce
nt
ag
e i
n 
th
e t
ab
le
 d
oe
s n
ot
 m
at
ch
 th
e c
ite
d
m
an
u
sc
rip
t, 
be
ca
us
e 
w
e 
us
ed
 2
30
0 
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 th
e 
de
no
m
in
at
or
 (H
CP
 on
ly)
 ra
the
r t
ha
n 2
60
0 (
HC
P a
nd
 pa
tie
nts
)
7 A
lth
ou
gh
 se
ro
ne
ga
tiv
ity
 st
at
us
 b
y 
ag
e 
gr
ou
p 
w
as
 m
en
tio
ne
d 
in
 th
e 
ar
tic
le
, w
e 
di
d 
no
t i
nc
lu
de
 it
 b
ec
au
se
 th
e 
pe
rc
en
ta
ge
 w
as
 c
al
cu
la
te
d 
by
 ta
ki
ng
 th
e 
nu
m
be
r i
n 
an
 a
ge
 g
ro
up
 w
ho
 w
er
e 
se
ro
ne
ga
tiv
e 
ou
t o
f
th
e 
to
ta
l n
um
be
r w
ho
 w
er
e 
se
ro
ne
ga
tiv
e 
(ra
the
r t
ha
n t
he
 nu
mb
er 
in 
a c
ert
ain
 ag
e g
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p w
ho
 w
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ron
eg
ati
ve
 ou
t o
f t
he
 to
tal
 nu
mb
er 
in 
tha
t a
ge
 gr
ou
p).
8 O
ur
 p
er
ce
nt
ag
es
 d
o 
no
t m
at
ch
 te
xt
 in
 th
e 
ci
te
d 
m
an
us
cr
ip
t, 
be
ca
us
e 
th
e 
au
th
or
s i
nc
lu
de
d 
th
e 
m
iss
in
g 
da
ta
 in
 th
e 
to
ta
l. 
W
e 
ex
cl
ud
ed
 th
e 
m
iss
in
g 
da
ta
 fr
om
 th
e 
nu
m
be
r w
ho
 w
er
e 
te
ste
d,
 b
ec
au
se
 th
e 
au
th
or
s
st
at
ed
 “
fo
r c
lin
ic
al
 re
as
on
s, 
se
ro
lo
gy
 n
ot
 in
di
ca
te
d”
.
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9 P
er
ce
nt
ag
es
 in
 th
is 
ce
ll 
do
 n
ot
 in
cl
ud
e 
eq
ui
vi
ca
l s
er
ol
og
ic
al
 te
st 
re
su
lts
 (a
ge
 br
ea
kd
ow
n b
y n
eg
ati
ve
 an
d e
qu
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ca
l s
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 w
as 
no
t a
va
ila
ble
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t p
ro
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su
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ep
tib
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s c
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w
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s a
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g 
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m
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ge
 w
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ifi
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 a
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te
d 
w
ith
 im
m
un
ity
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 m
ul
tiv
ar
ia
te
 a
na
ly
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, b
ut
 a
ge
 b
re
ak
do
w
n 
w
as
 n
ot
 p
ro
vi
de
d.
12
Th
e 
m
an
us
cr
ip
t r
ep
or
te
d 
th
e 
re
la
tiv
e 
ris
k 
by
 a
ge
 g
ro
up
, b
ut
 th
e 
sa
m
pl
e 
siz
e 
w
as
 su
ch
 a
 sm
al
l p
ro
po
rti
on
 o
f t
he
 to
ta
l n
um
be
r o
f H
CP
, t
ha
t w
e 
di
d 
no
t i
nc
lu
de
 th
e 
re
su
lts
 in
 th
e 
ta
bl
e.
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ea
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s b
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 c
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ia
n,
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te
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rti
le
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an
ge
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) a
nd
 m
ea
n v
alu
es,
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ud
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at 
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ed
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sti
ng
 a 
no
n r
ep
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en
tat
ive
 su
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et 
of 
he
alt
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 pe
rso
nn
el 
(i.
e. 
tho
se 
wi
tho
ut 
oth
er 
ev
ide
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e o
f m
ea
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s
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m
un
ity
) w
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de
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e s
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W
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n e
t a
l. 2
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d 2
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ffe
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t g
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ps
, o
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h w
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ub
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 ne
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lud
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 th
e s
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y b
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ly 
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p 
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w
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e
3 M
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n 
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m
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 m
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n 
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lue
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 of
 st
ud
ies
)
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